AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02388178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental toothpaste containing fluoride and amino acid (arginine)
Description: Brush whole mouth with study toothpaste 2x/day for the 2 week test period. Each brushing routine is 1 minute whole mouth brushing with oral retainer in mouth, spit out toothpaste residue and wait for 1 minute before rinsing with water.
Study NCT02388178 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoride toothpaste containing fluoride as the anti-cavity ingredient
Description: Brush whole mouth with study toothpaste 2x/day for the 2 week test period. Each brushing routine is 1 minute whole mouth brushing with oral retainer in mouth, spit out toothpaste residue and wait for 1 minute before rinsing with water.
Study NCT02388178 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluoride toothpaste containing fluoride as the anti-cavity ingredient
Description: Brush whole mouth with study toothpaste 2x/day for the 2 week test period. Each brushing routine is 1 minute whole mouth brushing with oral retainer in mouth, spit out toothpaste residue and wait for 1 minute before rinsing with water.
Study NCT02388178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoride toothpaste containing fluoride as the anti-cavity ingredient
Description: Brush whole mouth with study toothpaste 2x/day for the 2 week test period. Each brushing routine is 1 minute whole mouth brushing with oral retainer in mouth, spit out toothpaste residue and wait for 1 minute before rinsing with water.
Study NCT00981253 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMT-enhanced Cardiac Rehabilitation
Description: Standard exercise-based cardiac rehabilitation, three times per week, enhanced with weekly stress management training for 12 weeks.
Study NCT00981253 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Cardiac Rehabilitation
Description: Supervised exercise, three times per week, for 12 weeks.
Study NCT02390622 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Fecal microbiota transplantation
Description: bacteria liquid from 60g fecal was infusion via nasointestinal tube for three days
Study NCT02675257 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Goal setting towards improvement of glycaemic control
Description: Discussing and setting goals regarding improvements of suboptimal glycaemic control, depressive symptoms and diabetes distress
Study NCT02058056 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Irradiation: HA-PCI
Description: 25 Gy in 10 daily factions, five times a week
Study NCT02959905 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TSA-CTL
Description: Patients will receive TSA-CTL iv over 20-30 minutes on day 0.
Study NCT02675257 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes-specific problem-solving therapy
Description: Diabetes-specific problem-solving therapy with main focus on suboptimal glycaemic control, depressive symptoms and diabetes distress
Study NCT01247675 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omnitrope
Description: s.c., daily injection
Study NCT00621725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2171
Description: Oral dose
Study NCT01763203 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Care Management+Community Health Worker
Description: Over a period of a year subjects randomized into the Intervention arm of the study will receive support from a Care Manager. Subjects will also participate in educational group sessions on chronic disease self-management and have home visits by a Community Health Worker who will use mobile health technology.
Study NCT01763203 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Subjects randomized into the Usual Care arm will receive educational materials about stroke distributed to the Intervention patients and will receive their post-stroke care as usual.
Study NCT02985021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Chemotherapy
Study NCT02985021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Chemotherapy
Study NCT03180957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Study NCT03180957 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Study NCT03579121 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacogenomic (PGx)
Description: Administer a pharmacogenomics test (buccal swab) during the pre-operative setting
Study NCT03579121 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacogenomic (PGx)
Description: Administer a pharmacogenomics test (buccal swab) during the pre-operative setting
Study NCT02675257 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interventions to increase diabetes treatment motivation
Description: Interventions to increase diabetes treatment motivation in order to achieve improvements of glycaemic control as well as recovery from affective problems
Study NCT02675257 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Activation of personal and social resources
Description: Activation of personal and social resources with a view to diabetes control and affective problems
Study NCT03579121 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Review results
Description: Pharmacogenomic (PGx) results reviewed by the clinicians during their treatment and the results may guide clinical decisions.
Study NCT02204436 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Emulsion and gel
Description: A fixed similar quantity of both emulsion and gel were applied consequentially on the hand twice a day, in the morning and in the evening (preferentially always at the same hour), with a mild massage, until complete absorption, for 8 weeks.
Study NCT00741598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galantamine-ER
Description: Galantamine-ER 8 to 24 mg per day for 16 weeks
Study NCT00741598 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Galantamine placebo
Description: Galantamine placebo 8 to 24 mg per day for 16 weeks
Study NCT02742025 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inclusion visit
Description: This visit takes place between days -15 and -7 preceding a coronarography scheduled for Day 0. It is part of standard care and corresponds to a required cardiology consultation.
Study NCT02742025 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Inclusion visit
Description: This visit takes place between days -15 and -7 preceding a coronarography scheduled for Day 0. It is part of standard care and corresponds to a required cardiology consultation.
Study NCT02742025 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nurse consultation
Description: This visit takes place on the same day as the inclusion visit and includes practical advice concerning the hospital stay, explanations concerning the surgical act and practical advice on its implementation, information on the length of stay and after. An explanatory booklet concerning the surgical procedure is provided to the patient.
Study NCT02742025 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telephone contact
Description: A nurse will telephone the patient 72h to 48h before the coronarography scheduled for day 0. During the telephone conversation the nurse will assess the patient's knowledge about his/her pathology, his/her examination and the course of hospitalization. The nurse will answer any questions and if needed provide further information.
Study NCT02742025 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronarography on day 0
Description: This coronarography is scheduled as part of the patient's routine care. This is not an experimental intervention under evaluation.
Study NCT02742025 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Coronarography on day 0
Description: This coronarography is scheduled as part of the patient's routine care. This is not an experimental intervention under evaluation.
Study NCT03974529 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive running
Description: The patients who are assigned to this group will be required to finish a 90 minutes of training protocol, containing 30 minutes' warm-up stretching, and 60 minutes of supervised progressive aerobic endurance track running. The training takes place two time per week, for 24 weeks.
Study NCT03974529 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy
Description: The patients who are assigned to this group will be required to finish a 60 minutes of physiotherapy session. The training takes place once per week, for 24 weeks.
Study NCT04274075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-9545 Tablet, Fasted: Treatment A
Description: One dose of the GDC-9545 Phase 1 reference tablet formulation (three 10-mg tablets) administered orally with approximately 240 mL room temperature water after at least an 8-hour fast.
Study NCT02675257 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reduction of barriers to self-care/glycaemic control
Description: Definition and reduction of barriers to adequate diabetes self-care behaviour as well as good glycaemic control
Study NCT02675257 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive restructuring of diabetes-related problems
Description: Cognitive restructuring of diabetes-related problems such as suboptimal glycaemic control and diabetes-related affective problems
Study NCT02675257 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Goal definition regarding self-care/glycaemia/well-being
Description: Goal definition and agreement regarding diabetes self-care behaviour, optimal glycaemic control and activities supporting well-being and recovery from affective symptoms
Study NCT02675257 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health care and specific topics (e. g. blood pressure)
Description: Education on health care and specific topics (e. g. blood pressure)
Study NCT02675257 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy foods, cooking recommendations, recipes
Description: Education on healthy and unhealthy foods, cooking and recipes
Study NCT02675257 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sports, activities and exercise
Description: Education on sports, activities and exercise
Study NCT02959905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 500 mg/m2/day iv on day -5 for one day.
Study NCT02675257 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Foot care: exercises, care & control, injuries, neuropathy
Description: Education on foot care: exercises, care and control, injuries, and diabetic neuropathy
Study NCT02675257 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diabetes complications
Description: Education on diabetes complications
Study NCT02675257 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Social aspects of living with diabetes
Description: Education on social aspects of living with diabetes
Study NCT03748862 — intervention group
Intervention type: OTHER
Intervention: Taper Plan
Description: Occurrence of a taper plan defined by a primary care provider during the follow-up period. Evidence of a taper plan will be obtained by searching prescriptions (SIGs) and medical encounter notes using natural language processing (NLP).
Study NCT02261077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyoscine butylbromide
Study NCT02959905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 25 mg/m2/day iv over 30 minutes on day -5 and -4 for two days.
Study NCT02959905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 500 mg/m2/day iv on day -5 and -4 for two days.
Study NCT03821220 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational Interview support and Dietitian support
Description: Three sessions of a structured motivational support intervention. Each patient will be required to set a SMART physical activity personal objective. The sessions will cover possible barriers and facilitators, enhancing self-efficacy, and feedback. In addition two sessions with a dietitian to discuss ways to improve current health habits.
Study NCT03821220 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Activity tracker plus usual care
Description: Each patient will receive their own activity tracker (vivofit 3) with instructions on use, in addition to usual care, and written handouts for pre-diabetic patients.
Study NCT02261077 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02443753 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EndoBarrier SANS
Description: Eligible subjects will be implanted with the EndoBarrier® SANS™ Device for a period of 3 months. The GI Dynamics' EndoBarrier® SANS™ is an endoscopically positioned device that represents an alternative to the use of gastric bypass operative techniques as a means of re-routing food and altering the gut-hormone axis. The EndoBarrier® SANS™ provides an alternate passage of chime through the duodenum and proximal sixty centimeters of jejunum replicating in part the bypass of bariatric surgery.
Study NCT02171299 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Wound infiltration with local anaesthetic
Study NCT02171299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Study NCT04223544 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Influenza POC and laboratory testing
Description: Participation in the study is voluntary and carried out after the consent of the examined person. The examination consists of: 1) completing the questionnaire and 2) taking the throat swab twice by the researcher. Two throat swab samples will be taken at the same time. Both samples will be used for virological examination to determine the presence of influenza virus material using non-invasive tests: one sample will be analyzed by a quick 'on-site' test - Flu SensDx kit, while the other sample will be transported to the laboratory, where the reverse transcriptase polymerase chain reaction (RT-PCR) - reference method - will be performed to confirm the presence of influenza genetic material. Swabs are planned to be collected during the 2019/2020 influenza epidemic season (January-March).
Study NCT05614622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclopentolate Hydrochloride 1.0% eye drops
Description: A short-acting mydriatic agent
Study NCT00951470 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Follow -Up Visits
Description: If CDT is declined, participants will have follow-up visits at 1, 3, and 6 months after study interview.
Study NCT00951470 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Full CDT
Description: Monday through Friday visits to the clinic for 2 weeks of intensive outpatient therapy. The CDT will be done by the lymphedema therapist. Each session will last about 1 hour.~During the last 2 treatment visits (Visits 9 and 10), the participant will be taught how to do the CDT steps at home. Then, the CDT steps will be performed at home, every day for the next 3 months.
Study NCT00951470 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Modified CDT Program
Description: The participant will come to the clinic for 1-2 training sessions taught by the lymphedema therapist. Each training session will last about 1 hour, and the participant will be taught how to do the CDT steps at home. Then, the CDT steps will be performed at home, every day for the next 3 months.
Study NCT02900950 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multicolour inking specimens
Study NCT02900950 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Monocolour inking specimens
Study NCT04456387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection
Description: Participants received on-demand treatment, doses range from 30 IU/kg to 50 IU/kg, or doses divided on the discretion of the Investigator.
Study NCT04456387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection
Description: Participants received prophylaxis treatment at 50 IU/kg every three days.
Study NCT01083953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Comparing the optimal end-tidal concentration sevoflurane and desflurane for LMA extubation
Study NCT01083953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desflurane
Description: Comparing the optimal end-tidal concentration sevoflurane and desflurane for LMA extubation
Study NCT02646020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant
Description: aprepitant 125mg d1, 80mg d3 and d5; until pruritus recurrence or discontinuation of EGFR-TKI or safely issues (SAE etc.)
Study NCT02646020 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desloratadine
Description: Desloratadine 5mg d1-d28; until pruritus recurrence or discontinuation of EGFR-TKI or safely issues (SAE etc.)
Study NCT02646020 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo of aprepitant
Description: Placebo of aprepitant 125mg d1, 80mg d3 and d5; until pruritus recurrence or discontinuation of EGFR-TKI or safely issues (SAE etc.)
Study NCT02646020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of desloratadine
Description: Placebo of desloratadine 5mg d1-d28; until pruritus recurrence or discontinuation of EGFR-TKI or safely issues (SAE etc.)
Study NCT04538846 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Culinary art therapy
Description: Culinary art therapy is a novel approach which broadly perceives food and cooking as enabling participants to explore needs, patterns and relationships and facilitate therapeutic processes.
Study NCT02872558 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Acute Otitis Media Choice Decision Aid
Description: Decision Aid
Study NCT02872558 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Usual Care
Study NCT02357602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-7340
Description: Medication is supplied in 10 or 25mg tablets, so subjects will receive either 1/2 or one tablet in a single dose.
Study NCT02160730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-roscovitine
Description: See Arm Description
Study NCT03248544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vitamin D
Description: Fat-soluble vitamin D injection contain of 300,000 IU vitamin D that given via intramuscular injection
Study NCT03248544 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: control
Description: No intervention
Study NCT02323958 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupoint stimulation
Description: stimulation is given at acupoints
Study NCT02323958 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: non-acupoint stimulation
Description: stimulation is given at acupoints
Study NCT02323958 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electrode attached
Description: electrodes are attached to skin
Study NCT02323958 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: electrode attached
Description: electrodes are attached to skin
Study NCT02323958 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: electrode attached
Description: electrodes are attached to skin
Study NCT02323958 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electrical stimulation
Description: electrical stimulation is given through electrodes attached to th skin
Study NCT02323958 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: electrical stimulation
Description: electrical stimulation is given through electrodes attached to th skin
Study NCT05288829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN1210 SC
Description: All doses of ALXN1210 SC were administered by four 100-milligram (mg) SC injections of 1 milliliter (mL) each in the abdominal area. All four 1-mL injections were administered over a 15-minute period with at least 15 minutes between the end of injection in 1 participant and the start of injection in the next participant.
Study NCT05288829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN1210 IV
Description: All doses of ALXN1210 IV were administered by IV infusion, using IV sets with in-line filters, at a maximum rate of 333 mL/hour, excluding interruption for safety or technical reason. There were at least 15 minutes between the end-of-infusion/injection in 1 participant and the start-of infusion/injection in the next participant.
Study NCT05288829 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: All doses of placebo SC were administered by four 100-mg SC injections of 1 mL each in the abdominal area. All four 1-mL injections were administered over a 15-minute period with at least 15 minutes between the end of injection in 1 participant and the start of injection in the next participant.
Study NCT04389034 — intervention group
Intervention type: DRUG
Intervention: Pollinex Quattro with tree- and grass pollen extracts and their mixtures
Description: retrospective analysis of patient records of allergen-specific immunotherapy